Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$830.39 USD

830.39
342,620

+13.74 (1.68%)

Updated Nov 7, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds

by Kinjel Shah

Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.

Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal

by Zacks Equity Research

Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.

The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals

by Zacks Equity Research

Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) Stock Moves -0.71%: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $610.09, marking a -0.71% move from the previous day.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Merck & Toyota Motor

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $594.90 in the latest trading session, marking a -0.28% move from the prior day.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $591.13 in the latest trading session, marking a -1.09% move from the prior day.

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

by Zacks Equity Research

FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $586.84, moving -0.14% from the previous trading session.

Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?

by Zacks Equity Research

Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Regeneron (REGN) Stock Moves -0.79%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day.

Regeneron (REGN) Stock Moves -0.64%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $571.81 in the latest trading session, marking a -0.64% move from the prior day.

Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study

by Zacks Equity Research

Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use

by Kinjel Shah

European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.

Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year

by Zacks Equity Research

Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.

Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down

by Zacks Equity Research

Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.

Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.